(Q33488874)
Statements
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules (English)
E K Rowinsky
D A Noe
L B Grochow
S E Sartorious
M K Bowling
T L Chen
B G Lubejko